Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma

APMIS

Volumn 123, Issue 8, 2015, Pages 639-647

  Tasioudi, Konstantia E ^a   Sakellariou, Stratigoula ^a   Levidou, Georgia ^a   Theodorou, Dimitrios ^b   Michalopoulos, Nikolaos V ^b   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a   Saetta, Angelica A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

4E BP1; Esophageal carcinoma; Immunohistochemistry; Molecular analysis; P70S6K; PI3K AKT mTOR pathway

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PIK3CA PROTEIN, HUMAN; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; ESOPHAGUS CARCINOMA; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HIGH RESOLUTION MELTING ANALYSIS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PYROSEQUENCING; COHORT ANALYSIS; ESOPHAGEAL NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84937253598     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12398     Document Type: Article

References (40)

1. Guo XF, Zhu XF, Zhong GS, Deng BG. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. Dis Esophagus 2013;26:487-95.
2. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014;46:467-73.
3. Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 2013;32:253-65.
4. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82.
5. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
6. Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 2012;110:E1237-48.
7. Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, et al. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep 2013;30:623-36.
8. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009;69:4885-93.
9. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077-80.
10. El-Habr EA, Levidou G, Trigka EA, Sakalidou J, Piperi C, Chatziandreou I, et al. Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. Virchows Arch 2014;465:473-85.
11. Keld RR, Ang YS. Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalized medicine? World J Gastroenterol 2011;17:2781-90.
12. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. Lyon: IARC, 2010.
13. Tasioudi KE, Saetta AA, Sakellariou S, Levidou G, Michalopoulos NV, Theodorou D, et al. p-ERK activation in esophageal carcinomas: clinicopathological associations. Pathol Res Pract 2012;208:398-404.
14. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
15. Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 2013;19:2451-9.
16. Wei L, Xu Z. Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer 2011;129:275-84.
17. Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, et al. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2010;17:2486-93.
18. Yoshioka A, Miyata H, Doki Y, Yasuda T, Yamasaki M, Motoori M, et al. The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol Rep 2008;19:1099-107.
19. Salehi Z, Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 2006;39:404-9.
20. Phillips WA, Russell SE, Ciavarella ML, Choong DY, Montgomery KG, Smith K, et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer 2006;118:2644-6.
21. Mori R, Ishiguro H, Kimura M, Mitsui A, Sasaki H, Tomoda K, et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res 2008;145:320-6.
22. Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, Jang J, et al. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One 2012;7:e41655.
23. Hou J, Jiang D, Zhang J, Gavine PR, Xu S, Liu Y, et al. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma. Hum Pathol 2014;45:352-8.
24. Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, Takahashi K, et al. Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. Int J Oncol 2009;34:767-75.
25. Eom HS, Kim MS, Hur SY, Yoo NJ, Lee SH. Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas. Acta Oncol 2009;48:1084-5.
26. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905.
27. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005;280:25485-90.
28. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
29. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-23.
30. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev 2010;3:374-91.
31. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signalling. Cancer Res 2006;66:5618-23.
32. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002;277:31099-106.
33. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
34. Cohen JD, Gard JM, Nagle RB, Dietrich JD, Monks TJ, Lau SS. ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci 2011;124:75-87.
35. Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L, Schiffer D. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res 2009;29:3087-94.
36. Li XY, Zhang LQ, Zhang XG, Li X, Ren YB, Ma XY, et al. Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas. J Neurooncol 2011;103:453-8.
37. Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, et al. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas. Histopathology 2012;61:293-305.
38. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011;58:1054-63.
39. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010;116:5517-26.
40. Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008;122:1118-29.